Clinical Trial Update: Allogeneic Immunotherapy for Hematological Malignancies by Selective Depletion of Regulatory T Cells [Phase 3]

View source ↗

Summary

Phase 3 trial update on allogeneic immunotherapy for hematological malignancies focusing on selective depletion of regulatory T cells.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematological Malignancies

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Hematological Malignancies, Regulatory T Cell Depletion | Phase 3 | Status: UNKNOWN